The powerful new documentary special “Living Proof” will premiere on Hulu on Dec. 1 in honor of World AIDS Day. The ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 5 years ago, it would be worth $2,134.58 today based on a price of $128.61 for GILD at the time of writing.

The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ...

Bulevirtide proved to be effective up to 72 weeks in patients with chronic hepatitis D virus infection, regardless of whether ...

Deborah Telman, Gilead Sciences Inc.'s top lawyer for the past three years, is relinquishing her duties as general counsel ...

MODERATOR: Good morning and welcome, everyone, to today's press briefing from the U.S. Department of State's Africa Media Hub. Today, we are discussing the America First Global Health Strategy and the ...

Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today ...

Aspen Neuroscience raises $115M Series C to advance its autologous iPSC-derived Parkinson’s therapy, scale manufacturing.